Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cervical cancer-specific CAR-T cells
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cervical cancer-specific CAR-T cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by the Shenzhen Geno-Immune Medical Institute. The therapy is designed to treat patients with advanced, stage III/IV, or relapsed cervical cancer. It involves the genetic modification of a patient's own T-cells to express CARs that target specific tumor-associated antigens, including Ganglioside GD2, Glutamate carboxypeptidase 2 (PSMA), Mucin-1 (MUC1), and Mesothelin. These antigens are frequently overexpressed on the surface of cervical cancer cells. Once re-infused into the patient, the engineered T-cells recognize and bind to these targets, leading to the targeted destruction of the cancer cells. The therapy is currently being evaluated in a Phase 1/2 clinical trial (NCT03356795) to determine its safety, feasibility, and clinical efficacy.
- Other names
- Cervical cancer-specific CAR-T cellsCAR-T Cells for Cervical Cancer
02
Targets
MesothelinPSMA (Prostate-specific membrane antigen)GD2MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on Cervical cancer-specific CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cervical cancer-specific CAR-T cells.